Literature DB >> 11231936

Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease.

S Vermeire1, S Joossens, M Peeters, F Monsuur, G Marien, X Bossuyt, P Groenen, R Vlietinck, P Rutgeerts.   

Abstract

BACKGROUND & AIMS: Anti-Saccharomyces cerevisiae antibody (ASCA) is a serologic marker associated with Crohn's disease (CD). Although there is still discussion on its clinical value, several companies each promote their own ASCA assay to be used in the gastroenterologist's practice at considerable expense. The aim of this study was to determine whether different ASCA assays agree sufficiently well for the results to be used interchangeably.
METHODS: Blood obtained from a large cohort of IBD patients with inflammatory bowel disease (IBD; 100 with CD, 100 with ulcerative colitis [UC]) and 178 controls (100 healthy blood donors and 78 patients with non-IBD diarrheal illnesses) was studied with 4 different ASCA assays. Sensitivity, specificity, and positive predictive value were compared. Agreement between assays was evaluated.
RESULTS: Sensitivity of ASCA for CD ranged between 41% and 76%. Sensitivity was inversely related to specificity and positive predictive value. Results correlated well overall (range = 0.54-0.90) and the different ROC curves showed good agreement. When recalculated cutoff points were used, interchangeability increased. However, large differences were seen when absolute values were compared.
CONCLUSIONS: A large range in sensitivities and specificities of ASCA for CD is seen with different ASCA assays, mainly as a consequence of the cutoff value chosen for each individual assay. Although agreement between and within assays is good, caution is important when absolute values are used. Standardization of ASCA measurements is greatly needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11231936     DOI: 10.1053/gast.2001.22546

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  30 in total

Review 1.  Diagnostic methodologies: serology, endoscopy, and radiology.

Authors:  T Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2001-12

2.  Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy.

Authors:  I E A Hoffman; P Demetter; M Peeters; M De Vos; H Mielants; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

3.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

4.  Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.

Authors:  Eun Soo Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

5.  CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.

Authors:  B Vander Cruyssen; H Peeters; I E A Hoffman; D Laukens; P Coucke; D Marichal; C Cuvelier; E Remaut; E M Veys; H Mielants; M De Vos; F De Keyser
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 6.  Do we really understand what the immunological disturbances in inflammatory bowel disease mean?

Authors:  Epameinondas V Tsianos; Konstantinos Katsanos
Journal:  World J Gastroenterol       Date:  2009-02-07       Impact factor: 5.742

7.  Gastrointestinal-associated autoantibodies in different autoimmune diseases.

Authors:  Dana Ben-Ami Shor; Hedi Orbach; Mona Boaz; Arie Altman; Juan-Manuel Anaya; Nicola Bizzaro; Angela Tincani; Ricard Cervera; Gerard Espinosa; Ljudmila Stojanovich; Blaž Rozman; Stefano Bombardieri; Salvatore De Vita; Jan Damoiseaux; Danilo Villalta; Elio Tonutti; Renato Tozzoli; Ori Barzilai; Maya Ram; Miri Blank; Nancy Agmon-Levin; Yehuda Shoenfeld
Journal:  Am J Clin Exp Immunol       Date:  2012-05-25

8.  Diagnostic role and clinical association of ASCA and ANCA in Brazilian patients with inflammatory bowel disease.

Authors:  Renato Mitsunori Nisihara; Wilson Beleski de Carvalho; Shirley Ramos da Rosa Utiyama; Heda Amarante; Márcia Luiza Baptista
Journal:  Dig Dis Sci       Date:  2009-10-14       Impact factor: 3.199

9.  Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation.

Authors:  Anupa Kamat; Petronela Ancuta; Richard S Blumberg; Dana Gabuzda
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

10.  Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis.

Authors:  D Franchimont; S Vermeire; H El Housni; M Pierik; K Van Steen; T Gustot; E Quertinmont; M Abramowicz; A Van Gossum; J Devière; P Rutgeerts
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.